Navigation Links
HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance
Date:11/3/2009

10.0 0.12 Interest associated with UBS Settlement (6) (9.4) (0.11) Provision for income tax benefit (70.1) (0.84) Estimated income tax expense (5.0) (0.06) ---- ----- Adjusted income from continuing operations (1)(4) 72.6 0.87 Adjustment for dilution (2) (0.12) ----- Adjusted income from continuing operations per diluted share (2)(4) $0.75 ===== Estimated income tax expense 5.0 Interest expense and amortization of debt discounts and fees, excluding interest associated with UBS Settlement 168.9 Depreciation and amortization, excluding accelerated depreciation of corporate campus (3) 73.2 ---- 319.7 Other adjustments per the Company's Credit Agreement: Impairment charges, including investments 2.4 Net noncash loss on disposal of assets 2.0 Loss on early extinguishment of debt 5.9 Compensation expense under FASB Statement No. 123(R) 11.7 ---- Adjusted Consolidated EBITDA (1)(4)(5) $341.7 ====== Weighted average common shares outstanding: Basic 83.0
'/>"/>
SOURCE HealthSouth Corporation
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. HealthSouth Announces Date of 2009 Third Quarter Earnings Conference Call
2. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
3. Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia
4. ATSU Arizona Health & Technology Park Partner HealthSouth Holds Grand Opening
5. HealthSouth Comments on Civil Litigation
6. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
7. HealthSouth Announces Date of 2009 Second Quarter Earnings Conference Call
8. Court Rules in Favor of HealthSouth in Litigation Involving General Medicine, P.C.
9. HealthSouth to Present at 34th Annual Deutsche Bank Health Care Conference
10. HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009
11. HealthSouth to Present at Bairds 2009 Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... scientists have found the first potential immunological clue of ... the pandemic H1N1 virus. , The study analyzed ... 15 outpatients and 15 control subjects in 10 Spanish ... August 2009. Researchers from the Hospital Clinico Universitario de ... high levels of a molecule called interleukin 17 in ...
(Date:12/15/2009)... ATLANTA, GADecember 15, 2009Do good-looking people really benefit from ... researchers from the University of Georgia and the University ... to have more social relationships and therefore an increased ... and might be why we spend billions of dollars ... study, published in this month,s issue of Personal ...
(Date:12/15/2009)... Leading Workers, Compensation Carrier Confirms PMSI as Solution Provider ... ... Tampa, FL (Vocus) December 15, 2009 -- PMSI, ... providers of specialty products and services for the workers’ ... (KEMI) has decided to renew its pharmacy services (retail ...
(Date:12/15/2009)... deemed safer than wood fiber , , TUESDAY, Dec. 15 (HealthDay ... arm in a fall are much lower on playgrounds with ... new research has found. , Researchers at the Hospital for ... playground surfaces of either granite sand or engineered wood fiber. ... Medicine . , The risk of a broken arm resulting ...
(Date:12/15/2009)... study finds , , TUESDAY, Dec. 15 (HealthDay News) -- Tight ... with type 2 diabetes who have other medical problems, a ... in type 2 diabetes "has been a subject of controversy ... medicine at the University of California at Irvine, and lead ... the Annals of Internal Medicine . "Our work attempts ...
Breaking Medicine News(10 mins):Health News:First immunological clue to why some H1N1 patients get very ill or die 2Health News:The importance of attractiveness depends on where you live 2Health News:KEMI Renews Contract With PMSI 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 3
... EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-stage ... and inflammatory diseases,announced today that James S. Burns, ... overview at the Acumen BioFin Rodman & Renshaw ... New York Palace Hotel in,New York, November 5-7, ...
... BPUR ) announced today that the trading symbol ... to BPUR at the open of the market on,Wednesday, ... OTCBB,will revert to the following ticker symbols: BPREW reverting ... BPURL. Biopure Corporation Biopure Corporation develops, manufactures ...
... FRANCISCO, Calif., Oct. 31 Anesiva,Inc. (Nasdaq: ANSV ... chief executive officer, will present at the following events ... November 6, 2007 3:45 p.m. ET ... Healthcare Conference November 27, 2007 4:30 p.m. ...
... QUEBEC CITY, Oct. 31 /PRNewswire-FirstCall/ - AEterna Zentaris ... focused on,endocrine therapy and oncology, will announce its ... open on Wednesday, November,7, 2007. The Company will ... results on the same day at 10:00 a.m. ...
... NORTHAMPTON, Mass., Oct. 31 Physicians ... posts to Healthcommunities.com,Inc.,s healthchannels forum,( http://www.healthcommunities.com/health/forums.shtml ... physician post was submitted to the ... hosted and maintained by,Healthcommunities.com, Inc. (HC), ...
... ALTH ), a biopharmaceutical company focused on,the development ... cancer, today announced that Paul L. Berns, President and,CEO, ... BioFin Rodman &,Renshaw Conference in New York. The ... on,Tuesday, November 6, 2007. There will be a live ...
Other Medicine News:Health News:EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference 2Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2Health News:Free Site Offering Patient-Physician Dialog Reaches Milestone 2Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2
(Date:12/15/2009)... -- Masimo (Nasdaq: MASI ), the inventor ... Perfusion pulse oximetry, today announced that Masimo Chairman ... 2009 Frost & Sullivan CEO of the Year ... According to Frost & Sullivan, the award is ... in understanding customer requirements, developing new technologies, delivering ...
(Date:12/15/2009)... MALVERN, Pa. and WALTHAM, Mass., Dec. 15 /PRNewswire/ ... find that methicillin-resistant Staphylococcus aureus (MRSA) ... infectious disease specialists with regard to their treatment ... activity against MRSA is among the top factors ... skin and skin structure infections. Other key factors ...
(Date:12/15/2009)... -- Bend Research Inc. announced,today that its clients may ... used in technologies developed by the firm to enhance ... Bend Research clients may now reference a ... filings with the FDA, Bend Research officials said. , ... development and know it will assist our,clients in accelerating ...
Breaking Medicine Technology:Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 2Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 3Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 4Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 5Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 6A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2An atomic level look at an HIV accomplice 61728 1An atomic level look at an HIV accomplice 61728 2Bioreactor for bone tissue engineering wins professor venture fair 10813 1Bioreactor for bone tissue engineering wins professor venture fair 10813 2Bioreactor for bone tissue engineering wins professor venture fair 10813 3Drug studied as possible treatment for spinal injuries 10811 1Drug studied as possible treatment for spinal injuries 10811 2Drug studied as possible treatment for spinal injuries 10811 3
... in Repeat-Dosing Study in Subjects with ALS, RICHMOND, ... ) announced today that it has opened a Phase,2 ... subjects,with ALS, a progressive, degenerative motor-neuron disease for which ... drug, SB-509, is an injectable formulation of a plasmid,encoding ...
... Sept. 3 Forest Laboratories, Inc.,(NYSE: ... announced results from,two global Phase III studies ... for the treatment of patients with chronic,obstructive ... I&II,(AClidinium CLinical Trial Assessing Efficacy and Safety ...
Other Medicine Technology:Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: